13 Although a positive trend is visible in OS for TIL-NKI/CCIT therapy compared with ipilimumab, this difference did not (yet) reach statistical significance, despite profound differences in PFS. 13 Consequently, the beneficial effect on survival on TIL-NKI/CCIT treatment reflected in the (QA)LYs might currently be underestimated.
← all excerpts
Cost-effectiveness of treating advanced melanoma with tumor-infiltrating lymphocytes based on an international randomized phase 3 clinical trial.
1
—
—